Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
- Mechanism
- Curator reviewed
Endostatin is an endogenous antitumor protein. Endostatin is a 20-kDa C-terminal fragment derived from type XVIII collagen which inhibits cell proliferation and migration, and induces endothelial cell apoptosis and cell cycle arrest. It is proposed that endostatin's effects are due to inhibition of vascular endothelial growth factor (VEGF) tyrosine phosphorylation of KDR/F1k-1 (VEGF receptor 2), the cell surface receptor for VEGF. VEGF is an important mediator of angiogensis. Endostatin additionally blocks activation of extracellular signal related kinases, or ERK, protein 38 mitogen activated protein kinase, or p38 MAPK (signal transduction pathways involving kinases that couple growth factors to cell surface receptors), as well as focal adhesion kinase (p125FAK). Studies are being done to determine if endostatin has possible impact on other pathways, and may also target E-selectin and block activity of metalloproteinases 2, 9 and 13. There is further research into a possible mechanistic link involving endostatin's angiogenic and zinc binding ability.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.Curator reviewed
- Also known as
- Endostatins · Recombinant human endostatin
- Code names
- YH-16
Resolves to
What you can answer from here — as of December 05, 2025
Which drugs share a target with Endostatin, and which of those have an active Phase 3 trial?